LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression
Experimental & Molecular Medicine
;
: 514-522, 2008.
Artículo
en Inglés
| WPRIM
| ID: wpr-84651
ABSTRACT
Tumor migration/invasion is the main cause of tumor progression and STAT3 is needed to enhance tumor migration/invasion by up-regulating MMP-9. Thus, agents that inhibit STAT3 activation may be used as an anticancer drug. We present herein that 6-methyl-2-propylimino-6, 7-dihydro-5H-benzo [1, 3]-oxathiol- 4-one (LYR71) , a derivative of trimeric resveratrol, has an anticancer activity through inhibition of STAT3 activation. We found that LYR71 suppressed STAT3 activation and inhibited the expression and activity of MMP-9 in RANTES-stimulated breast cancer cells. In addition, LYR71 reduced RANTES-induced MMP-9 transcripts by blocking STAT3 recruitment, dissociating p300 and deacetylating histone H3 and H4 on the MMP-9 promoter. Furthermore, LYR71 inhibited tumor migration/invasion in RANTES-treated breast cancer cells and consequently blocked tumor progression in tumor-bearing mice. Taken together, the results of this study suggest that LYR71 can be therapeutically useful due to the inhibition effect of STAT3-mediated MMP-9 expression in breast cancer cells.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fosforilación
/
Estilbenos
/
Neoplasias de la Mama
/
Inmunohistoquímica
/
Estructura Molecular
/
Expresión Génica
/
Movimiento Celular
/
Supervivencia Celular
/
Western Blotting
/
Compuestos Bicíclicos Heterocíclicos con Puentes
Tipo de estudio:
Estudio pronóstico
Límite:
Animales
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Experimental & Molecular Medicine
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS